<DOC>
	<DOCNO>NCT00250393</DOCNO>
	<brief_summary>To establish efficacy 40 mg/day dos istradefylline change Unified Parkinson 's Disease Rating Scale ( UPDRS ) part-III ( Motor examination ) score patient Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>A Study Istradefylline ( KW-6002 ) Treatment Parkinson 's Disease</brief_title>
	<detailed_description>To establish efficacy 40mg/d dos istradefylline change UPDRS part-III ( Motor examination ) score patient Parkinson 's disease ( PD ) . Patients meet entry criterion randomly assign receive study drug 1 2 arm : Condition A ( dose 40mg/d istradefylline ) Period 1 followed Condition B ( match placebo ) Period 2 ( put 4 week interval phase two period ) Condition B Period 1 follow Condition A Period 2 ( put 4 week interval phase two period ) . Patients participate 12 week interim visit end treatment visit ass efficacy safety istradefylline .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>1 . UK Parkinson 's Disease Society ( UKPDS ) brain bank criterion ( Step 1 2 ) PD . 2 . PD stag 13 Modified Hoehn Yahr Scale . 3 . Be least 30 year age . 1 . Neurosurgical treatment PD . 2 . History psychosis . 3 . Diagnosis cancer within 5 year . 4 . Diagnosis clinically significant illness organ system . 5 . Minimental status examination score 25 less . 6 . Taking excluded medication . 7 . History drug alcohol abuse dependence within past two year . 8 . History seizures neurological malignant syndrome . 9 . Clinical depression . 10 . Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>monotherapy</keyword>
</DOC>